The Improving Medicaid Precision and Cancer Test Act of 2025 requires state Medicaid programs to cover lung cancer biomarker testing for their beneficiaries. Biomarker testing helps doctors identify specific genetic or molecular characteristics of a patient's cancer, which can guide treatment decisions and improve outcomes. This mandate affects Medicaid enrollees who are diagnosed with or at risk for lung cancer, as well as state Medicaid agencies that must ensure coverage is available. The bill does not specify particular funding amounts but requires the coverage to take effect on January 1, 2027, giving states time to implement the requirement. By mandating this coverage, the legislation aims to ensure that low-income and vulnerable populations have access to precision medicine tools that can help doctors provide more targeted and effective cancer treatment.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.